Search

U.S. FDA Approves Once-daily Jentadueto® XR (linagliptin and metformin hydrochloride extended-release) Tablets for Adults with Type 2 Diabetes

Jardiance® (empagliflozin) to be studied for the treatment of people with chronic heart failure

U.S. FDA approves Synjardy® (empagliflozin/metformin hydrochloride) tablets for adults with type 2 diabetes

Depression

Boehringer Ingelheim sees positive business momentum in 2020 despite impact of COVID-19

U.S. FDA approves Synjardy® XR (empagliflozin/metformin hydrochloride extended-release) tablets for adults with type 2 diabetes

Borderline Personality Disorder

FDA grants Fast Track designation to nintedanib for the treatment of systemic sclerosis with associated interstitial lung disease

Boehringer Ingelheim and Lilly expand heart failure program for Jardiance with new exercise capacity trials

BI & Lilly Announce Outcome of FDA Advisory Meeting | Boehringer Ingelheim US

The EASE phase III program includes two Phase III clinical trials to investigate the efficacy, safety and tolerability of once-daily Empagliflozin.

FDA Approves Jardiance® (empaglifozin) for T2D | BI US

Read more about the approval of Boehringer Ingelheim's third product from the BI-Lilly Diabetes alliance, JARDIANCE, used to treat type-2 diabetes.

Atrial Fibrillation

Boehringer Ingelheim and King’s College London join forces to progress new therapeutic concepts in major depressive disorder and schizophrenia

Fighting Non-Communicable Diseases | Boehringer Ingelheim US

Read more on Boehringer Ingelheim's new NCD initiative, aiming to reduce NCD prevalence and capture the impact of our product portfolio for our patients.

Boehringer Ingelheim and Zealand Pharma Advance to Phase 2 Clinical Testing in NASH and Obesity

2019 performance: stronger foundation to absorb global effects of COVID-19 pandemic

Boehringer Ingelheim and Eli Lilly and Company submit new drug application to FDA for empagliflozin, an investigational type 2 diabetes treatment

Technologies

We are expanding our global network of technology partners. Learn more about partnering with us.

Innovation in CNS Disease Research

More Potential

BI & Eli Lilly & Co. Update for TRADJENTA® & JENTADUETO® | Boehringer Ingelheim US

Read about the approved updates to the PI for Tradjenta® (linagliptin) tablets and Jentadueto® (linagliptin & metformin HCI). View ISI, PI and Med Guide.

Boehringer Ingelheim and Lilly announce positive top-line Phase III data results for empagliflozin as adjunct to insulin in type 1 diabetes

Tackling Health Disparities and Inequities for Women With Heart Failure: New Program Encourages Black and Latina Women to Demand More From Their Care

Tackling Health Disparities and Inequities for Women with Heart Failure: New Program Encourages Black and Latina Women to Demand More From Their Care

FDA approves Ofev® as first treatment for chronic fibrosing ILDs with a progressive phenotype

Yew Looi Liew Named President of U.S. Human Pharma for Boehringer Ingelheim Pharmaceuticals, Inc.

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers